Who founded Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals was founded by John Kollins in 2016.

Who are Satsuma Pharmaceuticals's investors?

Satsuma Pharmaceuticals's investors include OUP (Osage University Partners), Vivo Capital, Red Tree Venture.

How much funding has Satsuma Pharmaceuticals raised?

Satsuma Pharmaceuticals has disclosed $12.1M raised across 1 round.

Where is Satsuma Pharmaceuticals headquartered?

Satsuma Pharmaceuticals is headquartered in South San Francisco, US.

Satsuma Pharmaceuticals

South San Francisco, US · Founded 2016 · Delaware corporation · 3 known investors

Find your way into Satsuma Pharmaceuticals

316 people in our graph share verified history with the Satsuma Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Jennifer Savageunlockedknows Tom O'Neil · together at UCLA Anderson School of Management (overlapped)

knows the team · via Achieve Life Sciences

×6knows the team · via The University of Kansas

×4knows the team · via Pomona College

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.

Biotech Healthtech Medical Devices

Founders & leadership

Satsuma Pharmaceuticals was founded in 2016 by John Kollins.

John KollinsFounder

Tadayoshi IwashimaExecutive

Thomas B. King inPresident and Board DirectorThomas B. King is President and Board Director of Satsuma Pharmaceuticals. He brings over 40 years of experience in biopharmaceutical leadership, including prior roles as CEO, President, Executive Chair, and Board Chair across public and private biotechnology and specialty pharmaceutical companies.

Rob JanoskyChief Commercial Officer

Tom O'Neil inChief Financial OfficerHe brings over two decades of finance and operations experience across early-stage startups and large public companies, including expertise in capital raising, investor relations, business development, and merger and acquisition transactions.

David PrichardChief Operating Officer

Koji NakajimaHead of Corporate Strategy

Board

Heath LukatchBoard directorCo-Founder and Managing Partner at Red Tree Venture

Michael RiebeBoard director

Rajeev ShahBoard director

Investors · 3

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

Vivo CapitalPalo Alto · $10M – $50M

Red Tree VenturereportedSan Diegovia Heath Lukatch · board

Reported raises · per SEC filings

Form D private placements

$12.1M disclosed across 1 round · 2016

▶$12.1MraisedFeb 2018 · 4 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Heath LukatchDirector
John KollinsExecutive Officer, Director
Michael RiebeDirector
Rajeev ShahDirector
Tadayoshi IwashimaExecutive Officer
Thomas KingDirector

Offering amount: $12.3M
Amount sold: $12.1M
Minimum investment: $1
First sale: Dec 2016
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Medscape5 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Satsuma Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Ratefinance.yahoo.com · Mar 2023

Satsuma raises $62 million for nasal drug delivery tech - Drug Delivery Businessdrugdeliverybusiness.com · Apr 2019

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financingprnewswire.com · Apr 2019

Frequently asked questions

What does Satsuma Pharmaceuticals do?: Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.
Who founded Satsuma Pharmaceuticals?: Satsuma Pharmaceuticals was founded by John Kollins in 2016.
Who are Satsuma Pharmaceuticals's investors?: Satsuma Pharmaceuticals's investors include OUP (Osage University Partners), Vivo Capital, Red Tree Venture.
How much funding has Satsuma Pharmaceuticals raised?: Satsuma Pharmaceuticals has disclosed $12.1M raised across 1 round.
Where is Satsuma Pharmaceuticals headquartered?: Satsuma Pharmaceuticals is headquartered in South San Francisco, US.